Drug Profile


Alternative Names: EPI-743; Vincerenone

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Edison Pharmaceuticals
  • Developer Edison Pharmaceuticals; Sumitomo Dainippon Pharma; University of Florida; Yale University
  • Class Alkadienes; Benzoquinones; Cyclohexenes; Small molecules
  • Mechanism of Action Antioxidants; NQO1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mitochondrial disorders; Leigh disease; Friedreich's ataxia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Leigh disease
  • Phase II Friedreich's ataxia; Methylmalonic acidaemia; Mitochondrial disorders; Noise-induced hearing loss; Parkinson's disease; Rett syndrome
  • No development reported Gilles de la Tourette's syndrome

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Gilles-de-la-Tourette's-syndrome in USA (PO)
  • 01 Apr 2017 Efficacy data from a phase II trial in Friedreich's ataxia presented at the 69th Annual Meeting of the American Academy of Neurology (AAN- 2017)
  • 16 Apr 2016 Initial efficacy and safety data from a phase IIa trial in Parkinson's disease presented at the 68th Annual Meeting of the American Academy of Neurology (AAN - 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top